

## Prolia and Xgeva - (60mg/mL, 70mg/mL; Injection, Subcutaneous)

<b>Generic Name</b>	Denosumab	<b>Innovator</b>	Amgen
<b>Dosage</b>	60mg/mL, 70mg/mL; Injection, Subcutaneous	<b>Branded US Sales</b>	More Than \$1000 mn
<b>Probable FTF</b>	None	<b>Known Para IV Filers</b>	Less Than 5
<b>Other ANDA developers</b>	None	<b>Tentative Approvals</b>	None
<b>Final Approvals</b>	Less Than 5	<b>Generic Launches</b>	None
<b>Indication</b>	Prolia is a RANK ligand (RANKL) inhibitor indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture. Xgeva is a RANK ligand (RANKL) inhibitor indicated for Prevention of skeletal-related events in patients with bone metastases from solid tumors		
<b>Complexities</b>	Yes		

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.